Drug maker Golden Biotechnology Corp (國鼎生技) yesterday said that its new lung cancer drug has received approval from the US Food and Drug Administration (FDA) to enter second-stage clinical trials, paving the way for the medicine to hit the world market in 2017.
Hocena is the first chemical drug developed by the company. It has a higher profit margin than the other botanical drugs in the pipeline, the company said.
OUTSOURCING
The company yesterday signed an agreement to outsource the second-phase clinical trials to global contract research organization Icon Holdings Corp. Icon will conduct the trials in the US and Taiwan first, based on the agreement.
Golden Biotechnology plans to spend US$10 million on clinical trials, company chairman Alex Liu (劉勝勇) told a media briefing yesterday.
“We expect the drug to hit the market within 20 months, as the US government has allowed the drug to enter the fast track,” meaning it can skip third-phase clinical trials, he said.
There is currently no drug that can cure lung cancer, but the new approach offered by Hocena to treat the disease could give new hope to lung cancer patients, Liu said.
OTHER CANCER TYPES
Aside from lung cancer, Golden Biotechnology also plans to test Hocena for treatment of pancreatic cancer, colorectal cancer and leukemia when the drug passes the first part of phase two clinical trials within the next six to 10 months, said Chen Chih-ming (陳志銘), director of the company’s research and development department.
The market for lung cancer and pancreatic cancer drugs is estimated at about US$6.5 billion a year, according to Golden Biotechnology. That is less than a 10th of the overall market for cancer drugs last year, at US$80 billion.
CAPITAL EXPANSION
The company plans to expand its capital to about NT$1 billion (US$33.7 million) from NT$700 million now by the end of this year to fund the clinic trials.
Farglory Group (遠雄集團), which has a 20 percent stake in the company, is its largest shareholder, followed by three companies set up by Global Mixed-mode Technology Inc (致新科技) chairman Hsieh Nan-chiang (謝南強), which own 10 percent of the shares.
Golden Biotechnology expects to narrow its loss to NT$64.44 million in the first half of this year, from a loss of NT$83.39 million in the same period last year.
Chief financial officer Jackson Huang (黃士旗) said the company is unlikely to turn a profit by the end of next year because it has to spend money on clinical trials.
TARIFF TRADE-OFF: Machinery exports to China dropped after Beijing ended its tariff reductions in June, while potential new tariffs fueled ‘front-loaded’ orders to the US The nation’s machinery exports to the US amounted to US$7.19 billion last year, surpassing the US$6.86 billion to China to become the largest export destination for the local machinery industry, the Taiwan Association of Machinery Industry (TAMI, 台灣機械公會) said in a report on Jan. 10. It came as some manufacturers brought forward or “front-loaded” US-bound shipments as required by customers ahead of potential tariffs imposed by the new US administration, the association said. During his campaign, US president-elect Donald Trump threatened tariffs of as high as 60 percent on Chinese goods and 10 percent to 20 percent on imports from other countries.
Taiwanese manufacturers have a chance to play a key role in the humanoid robot supply chain, Tongtai Machine and Tool Co (東台精機) chairman Yen Jui-hsiung (嚴瑞雄) said yesterday. That is because Taiwanese companies are capable of making key parts needed for humanoid robots to move, such as harmonic drives and planetary gearboxes, Yen said. This ability to produce these key elements could help Taiwanese manufacturers “become part of the US supply chain,” he added. Yen made the remarks a day after Nvidia Corp cofounder and chief executive officer Jensen Huang (黃仁勳) said his company and Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) are jointly
United Microelectronics Corp (UMC, 聯電) expects its addressable market to grow by a low single-digit percentage this year, lower than the overall foundry industry’s 15 percent expansion and the global semiconductor industry’s 10 percent growth, the contract chipmaker said yesterday after reporting the worst profit in four-and-a-half years in the fourth quarter of last year. Growth would be fueled by demand for artificial intelligence (AI) servers, a moderate recovery in consumer electronics and an increase in semiconductor content, UMC said. “UMC’s goal is to outgrow our addressable market while maintaining our structural profitability,” UMC copresident Jason Wang (王石) told an online earnings
MARKET SHIFTS: Exports to the US soared more than 120 percent to almost one quarter, while ASEAN has steadily increased to 18.5 percent on rising tech sales The proportion of Taiwan’s exports directed to China, including Hong Kong, declined by more than 12 percentage points last year compared with its peak in 2020, the Ministry of Finance said on Thursday last week. The decrease reflects the ongoing restructuring of global supply chains, driven by escalating trade tensions between Beijing and Washington. Data compiled by the ministry showed China and Hong Kong accounted for 31.7 percent of Taiwan’s total outbound sales last year, a drop of 12.2 percentage points from a high of 43.9 percent in 2020. In addition to increasing trade conflicts between China and the US, the ministry said
RSS